TPST insider buying and SEC filings, explained
Tempest Therapeutics, Inc. · CIK 1544227
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$1.0M
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 24, 2026 | Other purchase | Matthew Angel (CEO and Director) bought 462,964 shares in 2 share classes indirectly (by entity); the filing does not report a price. New position of 231,482 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 23, 2026 |
| Mar 24, 2026 | Purchase (code P) | Matthew Angel (CEO and Director) bought 231,482 shares indirectly (by entity) at $2.16 ($500K), reported as a purchase (code P). New position of 231,482 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 23, 2026 |
| Mar 24, 2026 | Purchase (code P) | Matthew Angel (CEO and Director) bought 231,482 shares indirectly (by entity) at $2.16 ($500K), reported as a purchase (code P). New position of 231,482 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 25, 2026 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TPST in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.